These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 15073852)

  • 1. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ; Partin AW; Epstein JI; Walsh PC
    Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
    Hong SK; Han BK; Chung JS; Park DS; Jeong SJ; Byun SS; Choe G; Lee SE
    BJU Int; 2008 Nov; 102(9):1092-6. PubMed ID: 18671786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy.
    Freedland SJ; Aronson WJ; Presti JC; Amling CL; Terris MK; Trock B; Kane CJ
    Cancer; 2004 Apr; 100(8):1633-8. PubMed ID: 15073850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels.
    Freedland SJ; Aronson WJ; Kane CJ; Terris MK; Presti JC; Trock B; Amling CL
    Cancer; 2004 Aug; 101(4):748-53. PubMed ID: 15305405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
    Kordan Y; Chang SS; Salem S; Cookson MS; Clark PE; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA
    J Urol; 2009 Nov; 182(5):2291-5. PubMed ID: 19758638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
    Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
    Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy.
    DeCastro GJ; McCann T; Benson MC; McKiernan JM
    Urology; 2008 Dec; 72(6):1214-8. PubMed ID: 18597825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
    Polascik TJ; Mayes JM; Sun L; Madden JF; Moul JW; Mouraviev V
    Prostate; 2008 Sep; 68(13):1380-6. PubMed ID: 18543281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH database.
    Freedland SJ; Amling CL; Terris MK; Presti JC; Aronson WJ; Elashoff D; Kane CJ;
    Prostate Cancer Prostatic Dis; 2003; 6(3):261-5. PubMed ID: 12970733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.
    Blute ML; Bostwick DG; Bergstralh EJ; Slezak JM; Martin SK; Amling CL; Zincke H
    Urology; 1997 Nov; 50(5):733-9. PubMed ID: 9372884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.